Ledger.Open graph →
SEC Form D · Amendment · filed July 22, 2021

Tallac Therapeutics, Inc

Offering
$61.6M
Sold
$61.6M
Exemption
Rule 506(b)
Industry
Other Health Care
Location
BURLINGAME, CA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (20)

Mark Swanson · Tampa, FLDirectorJaume Pons · Burlingame, CADirectorAndrew Menlove · SALT LAKE CITY, UTDirectorGreg Moritz · Marietta, GADirectorShreyans Jain · Frisco, TXExec · DirectorIsaac Cheng · Burlingame, CADirectorWeston Reynolds · New York, NYDirectorChristopher Rising · Los Angeles, CADirectorJonathan Davila · Tampa, FLExec · DirectorChristine Brennan · Burlingame, CADirectorRan Geng · Burlingame, CADirectorMatthew Leyrer · Dallas, TXDirectorRan Geng · Burlingame, CADirectorMichael Carusi · Burlingame, CADirectorScott Mcmullin · Los Angeles, CADirectorHong Wan · Burlingame, CAExec · DirectorCorey Goodman · Burlingame, CADirectorConnor Mclaughlin · NEW YORK, NYDirectorJosh Sharkey · Cortlandt Manor, NYDirectorTally Ringwood · SALT LAKE CITY, UTDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗